News
CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with ...
5hon MSN
Find insight on Roche, Bangkok Dusit Medical Services, ResMed and more in the latest Market Talks covering the health care ...
The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...
22h
Medpage Today on MSNAdjuvant Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous SCCCHICAGO -- Adjuvant cemiplimab (Libtayo) significantly improved disease-free survival (DFS) compared with placebo in patients ...
8h
GlobalData on MSNRegeneron to acquire rights for Hansoh’s HS-20094 therapyRegeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...
Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...
The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...
Multiple myeloma (MM) is an incurable haematological malignancy, but patient survival outcomes have been lately improved by recent advances in treatment. Despite this innovation, however, MM patients ...
The candidate, named KT-621, is being positioned as a potential oral competitor to Sanofi and Regeneron's blockbuster ...
RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to Sector Perform from Outperform, ...
EVgo got the attention of a major investment bank. There's plenty to like - along with 3 roadblocks.
EVGo shares, however, have doubled in the last 12 months and have gained nearly 60% in the last three months, far outpacing the S&P 500 index SPX in both time frames.
Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results